Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2009 May;6(5):255-6.
doi: 10.1038/nrclinonc.2009.47.

Hematology: Bortezomib in newly diagnosed multiple myeloma

James R Berenson  1
Affiliations
Comment

Hematology: Bortezomib in newly diagnosed multiple myeloma

James R Berenson. Nat Rev Clin Oncol. 2009 May.

Abstract

Preclinical studies have shown that new agents such as bortezomib not only demonstrate anti-multiple-myeloma activity as single agents but also enhance the efficacy of both chemotherapy and steroids. A randomized trial has established that bortezomib not only improves response rates but also prolongs the lives of patients with multiple myeloma who are not candidates for high-dose chemotherapy.

PubMed Disclaimer

Comment on

  • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
    San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; VISTA Trial Investigators. San Miguel JF, et al. N Engl J Med. 2008 Aug 28;359(9):906-17. doi: 10.1056/NEJMoa0801479. N Engl J Med. 2008. PMID: 18753647 Clinical Trial.

References

    1. Clin Cancer Res. 2003 Mar;9(3):1136-44 - PubMed
    1. Br J Haematol. 2006 Oct;135(2):174-83 - PubMed
    1. N Engl J Med. 2008 Aug 28;359(9):906-17 - PubMed
    1. Clin Cancer Res. 2009 Feb 1;15(3):1069-75 - PubMed
    1. J Clin Oncol. 2008 Oct 10;26(29):4777-83 - PubMed

MeSH terms